Skip to Content
Merck
CN

SML3814

Sigma-Aldrich

Firibastat

≥98% (HPLC)

Synonym(s):

QGC-001, (3S)-3-Amino-4-[[(2S)-2-amino-4-sulfobutyl]disulfanyl]butane-1-sulfonic acid, (3S,3′S)-4,4′-Dithiobis(3-aminobutane-1-sulfonic acid, QGC 001, QGC001, RB 150, RB-150, RB150

Sign Into View Organizational & Contract Pricing

Select a Size

About This Item

Empirical Formula (Hill Notation):
C8H20N2O6S4
CAS Number:
648927-86-0
Molecular Weight:
368.51
MDL number:
MFCD20921962
UNSPSC Code:
12352200
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

H2O: 2 mg/mL, clear (Warmed)

storage temp.

-10 to -25°C

Related Categories

Biochem/physiol Actions

Firibastat (RB150; QGC001) is an orally active, blood-brain barrier-permeant prodrug composed of two molecules of disulfide-linked aminopeptidase A (APA; glutamyl aminopeptidase) active-site inhibitor EC33 (Ki = 300 nM) that are released via the action of brain reductase in the brain. Firibastat exhibits antihypertensive efficacy in vivo (Blood pressure reduction ED50 = 30 mg/kg via p.o. in spontaneously hypertensive rats).
Orally active, brain-permeant precursor of the aminopeptidase A (APA; glutamyl aminopeptidase) active-site inhibitor EC33 with antihypertensive efficacy in vivo.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000269512
0000269510
0000255770
0000255770
0000269512

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Central antihypertensive effects of chronic treatment with RB150: an orally active aminopeptidase A inhibitor in deoxycorticosterone acetate-salt rats
Journal of Hypertension, 36(3), 641-650 (2018)
Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension
Proceedings of the National Academy of Sciences of the USA, 101(20), 7775-7780 (2004)
Brain ACE2 activation following brain aminopeptidase A blockade by firibastat in salt-dependent hypertension
Clinical Science (London, England : 1979), 135(6), 775-791 (2021)
Effects of firibastat in combination with enalapril and hydrochlorothiazide on blood pressure and vasopressin release in hypertensive DOCA-salt rats
Biomedicine and Pharmacotherapy, 40, 111682-111682 (2021)
Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension
Hypertension, 51(5), 1318-1325 (2008)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service